Amedeo Smart

Free Medical Literature Service

 

Amedeo

Lung Cancer
  Free Subscription

Articles published in
Cancer Sci
    March 2026
  1. TSURUDA T, Kodama M, Nakayama KI
    Small Cell Lung Cancer Establishes a Metabolic Autocrine Mechanism Through Active Extracellular ATP Transport.
    Cancer Sci. 2026 Mar 2. doi: 10.1111/cas.70350.
    >> Share

  2. ONO Y, Otsu H, Masuda T, Kosai K, et al
    PSMD12 Overexpression Promotes Lung Adenocarcinoma Progression via Ubiquitin-Proteasome Pathway Dysregulation.
    Cancer Sci. 2026;117:644-656.
    >> Share

    February 2026
  3. KURIBAYASHI T, Nishimura J, Okawa S, Taoka M, et al
    TGF-beta Inhibitor Potentiates Osimertinib-Induced Anti-Tumor Immunity in Egfr-Mutant Lung Cancer.
    Cancer Sci. 2026 Feb 27. doi: 10.1111/cas.70352.
    >> Share

  4. KONO K, Tanino R, Tsubata Y, Haque EF, et al
    Microtubule Inhibitors Induce Cross-Resistance to Osimertinib Through CaMKII Activation in EGFR-Mutated NSCLC.
    Cancer Sci. 2026;117:418-428.
    >> Share

  5. LUO X, Xu J, Wang Z, Wang X, et al
    Spatial Location of SPP1(+)TAMs and Mutually Exclusive Subsets Based on Single-Cell and Transcriptome Data.
    Cancer Sci. 2026;117:548-565.
    >> Share

    January 2026
  6. NAM SY, Jo J, Choi SH
    Effect Modification by Cofactors in the Impact of Body Mass Index Change on the Risk of Lung Cancer.
    Cancer Sci. 2026 Jan 23. doi: 10.1111/cas.70332.
    >> Share

  7. SATO S, Yilmaz N, Arai S, Sakai K, et al
    MET Enhances Amivantamab Binding to EGFR and Antibody-Dependent Cellular Toxicity.
    Cancer Sci. 2026;117:118-129.
    >> Share

    December 2025
  8. SALEH MF, Nita A, Ohta Y, Kobayashi A, et al
    Hippo Pathway Drives Durable Non-Cell-Autonomous Ferroptosis Resistance in Lung Cancer.
    Cancer Sci. 2025 Dec 23. doi: 10.1111/cas.70299.
    >> Share

  9. TANAKA F, Watanabe Y, Sugawara S, Okami J, et al
    Perioperative Nivolumab in Resectable Non-Small Cell Lung Cancer: A Subanalysis of Japanese Patients From Checkmate 77T.
    Cancer Sci. 2025 Dec 23. doi: 10.1111/cas.70300.
    >> Share

  10. OKADA M, Sugawara S, Watanabe Y, Saito H, et al
    IMpower010: 5-Year Outcomes of Atezolizumab in Japanese Patients With Resected Stage IB-IIIA Non-Small Cell Lung Cancer.
    Cancer Sci. 2025 Dec 19. doi: 10.1111/cas.70297.
    >> Share

  11. YOSHIOKA H, Nishio M, Ohashi K, Osoegawa A, et al
    Atezolizumab + Chemotherapy for Advanced Non-Small Cell Lung Cancer in Japanese Clinical Practice (J-TAIL-2).
    Cancer Sci. 2025 Dec 11. doi: 10.1111/cas.70242.
    >> Share

  12. TAKAYAMA-ISAGAWA Y, Komura D, Isagawa T, Amano Y, et al
    A Transcriptomic Analysis of Cancer-Stromal Interactome in Lung Cancer Xenograft Models.
    Cancer Sci. 2025 Dec 11. doi: 10.1111/cas.70270.
    >> Share

  13. LI J, Zhao F, Wang Z, Yang S, et al
    KAT2A Deficiency Suppresses Lung Cancer Progression by Downregulating MYC Through Decreasing MYC Succinylation.
    Cancer Sci. 2025 Dec 9. doi: 10.1111/cas.70286.
    >> Share

  14. TOZUKA T, Noro R, Naito Y, Miura N, et al
    ACTN4 Gene Amplification and Actinin-4 Protein Expression for Osimertinib Efficacy in EGFR-Mutant NSCLC.
    Cancer Sci. 2025;116:3367-3375.
    >> Share

  15. LIU SY, Lin LT, Chang CH, Chen YJ, et al
    Liposomal (188)Rhenium Plus Macrophage Depletion Enhances Anti-PD-L1 Efficacy and B Cell Infiltration Against Lung Metastatic Cancer.
    Cancer Sci. 2025;116:3442-3458.
    >> Share

    November 2025
  16. JIANG Y, Liang Q, Zhu Y, Liang X, et al
    Third-Generation EGFR-TKIs Combined With Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Real-World Study.
    Cancer Sci. 2025 Nov 28. doi: 10.1111/cas.70269.
    >> Share


  17. Correction to "Trametinib Overcomes KRAS-G12V-Induced Osimertinib Resistance in a Leptomeningeal Carcinomatosis Model of EGFR-Mutant Lung Cancer".
    Cancer Sci. 2025 Nov 24. doi: 10.1111/cas.70278.
    >> Share

  18. WEI T, Cao W, Zhang Q, Wu E, et al
    Pulmonary Delivery of TCR Bispecific Proteins via Mesenchymal Stem Cells Facilitates Efficient Clearance of Lung Cancers.
    Cancer Sci. 2025;116:3185-3195.
    >> Share

  19. KIWAKI T, Tanaka H, Kawaguchi M, Umekita Y, et al
    Low-Density Lipoprotein Receptor-Related Protein 11 Promotes Proliferation in Lung Adenocarcinoma.
    Cancer Sci. 2025;116:3090-3101.
    >> Share

  20. KITAZONO S, Ono A, Kawamura T, Hataji O, et al
    Amivantamab Plus Chemotherapy in Japanese Patients With EGFR Exon 20 Insertions NSCLC.
    Cancer Sci. 2025;116:3139-3148.
    >> Share

  21. CHEN J, Pan Y, Zhang B, Li M, et al
    Comparison of the Efficacy of Different First-Line Therapies for EGFR L858R-Mutated NSCLC Patients With Brain Metastases.
    Cancer Sci. 2025;116:3125-3138.
    >> Share

    October 2025
  22. TAKAOKA H, Terai H, Nakamura K, Mizuno T, et al
    Clinical Application of In-House Comprehensive Genomic Profiling for Thoracic Cancer: Insights From a Japanese Hospital.
    Cancer Sci. 2025;116:2819-2830.
    >> Share

  23. TERASHIMA Y, Park S, Ikeuchi H, Hayashi T, et al
    Discovery of Novel RASGRF2 Fusions as a Therapeutic Target in Lung Adenocarcinoma of Never or Light Smokers.
    Cancer Sci. 2025;116:2868-2881.
    >> Share

  24. NGUYEN TTN, Chen PY, Zheng MY, Lin TK, et al
    Intrinsic PDL1 Signaling Modulates TGFBI-Mediated Growth Suppression in Lung Adenocarcinoma.
    Cancer Sci. 2025;116:2737-2749.
    >> Share

  25. ZHANG Z, Wang C, Guo Y, Zhao Z, et al
    HROB Induces Lung Adenocarcinoma Progression via ZC3HC1-CCNB1 Axis Regulation and Cell Cycle Dysregulation.
    Cancer Sci. 2025;116:2699-2711.
    >> Share

    September 2025
  26. ZENKE Y, Shiraishi Y, Goto Y, Azuma K, et al
    Durvalumab Post Concurrent Chemoradiotherapy in Japanese Patients With Limited-Stage Small-Cell Lung Cancer in the Phase 3 ADRIATIC Trial.
    Cancer Sci. 2025 Sep 21. doi: 10.1111/cas.70188.
    >> Share

  27. YANG W, Wu X, Cai F, Guo Z, et al
    NFATc4 Promotes Lung Adenocarcinoma Progression via the CCNB1/CDK1 Pathway and Is a Potential Prognostic Biomarker.
    Cancer Sci. 2025;116:2400-2412.
    >> Share

  28. HORI K, Tanaka I, Sato T, Sato M, et al
    PBK Expression Promotes the Aggressive Phenotypes of Mesothelioma.
    Cancer Sci. 2025;116:2413-2426.
    >> Share

    August 2025
  29. MO X, He J, Shen X, Li C, et al
    Connexin43 Promotes the Invasion and Metastasis of Lung Squamous Cell Carcinoma via GJIC-Dependent Ca(2+)/ERK Signaling Activation.
    Cancer Sci. 2025;116:2086-2100.
    >> Share

  30. YOKOYAMA T, Saitoh M, Miyazawa K
    TGF-beta Enhances Doxorubicin Resistance and Anchorage-Independent Growth in Cancer Cells by Inducing ALDH1A1 Expression.
    Cancer Sci. 2025;116:2176-2188.
    >> Share

  31. KIJIMA T, Kato T, Goto Y, Kuribayashi K, et al
    KEYNOTE-A17: First-Line Pembrolizumab Plus Cisplatin-Pemetrexed in Japanese Participants With Advanced Pleural Mesothelioma.
    Cancer Sci. 2025;116:2208-2217.
    >> Share

  32. WEI T, Cheng Y, Ge J, Zhu M, et al
    The Pro-Apoptotic Effect of Glucose Restriction in NSCLC via AMPK-Regulated Circadian Clock Gene Bmal1.
    Cancer Sci. 2025;116:2101-2112.
    >> Share

    July 2025
  33. HOSOYA K, Ozasa H, Yoshida H, Ajimizu H, et al
    Novel TEAD1 Inhibitor VT103 Enhances Dabrafenib Efficacy in BRAF V600E Mutated Lung Adenocarcinoma via Survivin Downregulation.
    Cancer Sci. 2025;116:1883-1896.
    >> Share

    June 2025
  34. MEN B, Chen Z, Ge H, Yang Z, et al
    Dauricine Overcomes Osimertinib Resistance in Lung Cancer by Inducing Ferroptosis via Stabilizing SAT1.
    Cancer Sci. 2025 Jun 8. doi: 10.1111/cas.70113.
    >> Share

  35. HONGU T, Sarenqiqige, Shandan, Kusunoki H, et al
    Permeable Lung Vasculature Creates Chemoresistant Endothelial Niche by Producing SERPINE1 at Breast Cancer Metastatic Sites.
    Cancer Sci. 2025;116:1604-1615.
    >> Share

  36. ZHANG Y, Xu Y, Jin H, Liu T, et al
    Spatial Heterogeneity of PD-L1 Expression as a Biomarker for Third-Generation EGFR-TKI Response in Advanced EGFR-Mutant NSCLC.
    Cancer Sci. 2025;116:1648-1660.
    >> Share

  37. HUANG J, Yuan Y, Guo L, Xia G, et al
    The impact of BTK knockdown on lung adenocarcinoma growth and immune response.
    Cancer Sci. 2025;116:1550-1564.
    >> Share

    May 2025
  38. MIYASHITA Y, Tajima K, Izumi K, Matsumoto N, et al
    Novel Approach to Overcome Osimertinib Resistance Using Bromodomain and Extra-Terminal Domain Inhibitors.
    Cancer Sci. 2025;116:1392-1404.
    >> Share

  39. MONIWA K, Tokita S, Sumi T, Saijo H, et al
    Loss of Tapasin in Tumors Potentiates T-Cell Recognition and Anti-Tumor Effects of Immune Checkpoint Blockade.
    Cancer Sci. 2025;116:1203-1213.
    >> Share

    April 2025
  40. OCHI T, Fujiki R, Fukuyo M, Rahmutulla B, et al
    Association of Intratumoral Bacterial Abundance With Lung Cancer Prognosis in Chiba University Hospital Cohort.
    Cancer Sci. 2025 Apr 11. doi: 10.1111/cas.70080.
    >> Share

  41. UTSUMI T, Mizuta H, Seto Y, Uchibori K, et al
    AXL-Mediated Drug Resistance in ALK-Rearranged NSCLC Enhanced by GAS6 From Macrophages and MMP11 Positive Fibroblasts.
    Cancer Sci. 2025;116:1034-1047.
    >> Share

  42. LI H, Tang C, Zhao P, Zhong R, et al
    Multiple Kinase Small Molecule Inhibitor Tinengotinib (TT-00420) Alone or With Chemotherapy Inhibit the Growth of SCLC.
    Cancer Sci. 2025;116:951-965.
    >> Share

  43. DING J, Wang X, Yang H, Zhang L, et al
    IGF2BP3 Triggers STAT3 Pathway by Stabilizing SRC RNA in an m6A-Dependent Manner to Promote Lymphatic Metastasis in LUAD.
    Cancer Sci. 2025;116:936-950.
    >> Share

  44. LIU X, Yu D, Yu Z, Su S, et al
    LHPP-P38 MAPK/ERK-ETS1 Axis Negative Feedback Signaling Restrains Progression in Breast Cancer.
    Cancer Sci. 2025;116:923-935.
    >> Share

  45. WANG P, Xu J, You W, Li J, et al
    CYP24A1 Binding to FUS Maintains Tumor Properties by Regulating the miR-200c/ZEB1/EMT Axis.
    Cancer Sci. 2025;116:910-922.
    >> Share

    March 2025

  46. Correction to "Celastrol Induces Proteasomal Degradation of FANCD2 to Sensitize Lung Cancer Cells to DNA Crosslinking Agents".
    Cancer Sci. 2025 Mar 29. doi: 10.1111/cas.70066.
    >> Share

  47. SHEN S, Wu Y, Shao Z, Li Y, et al
    LTF as a Potential Predictive Biomarker for Durable Benefit From First-Line Chemo-Immunotherapy in Small Cell Lung Cancer.
    Cancer Sci. 2025 Mar 17. doi: 10.1111/cas.70049.
    >> Share

  48. SAKAMOTO S, Inoue H, Takino T, Kohda Y, et al
    Claudin-11 Enhances Invasive and Metastatic Abilities of Small-Cell Lung Cancer Through MT1-MMP Activation.
    Cancer Sci. 2025 Mar 13. doi: 10.1111/cas.70038.
    >> Share

  49. ZHANG Y, Xu Y, Xu J, Zhong H, et al
    Osimertinib for EGFR-Mutant NSCLC Patients With Acquired T790M and EGFR Amplification After First-Generation EGFR-TKI Resistance.
    Cancer Sci. 2025;116:753-763.
    >> Share

  50. ZHU P, Li Z, Sun Y, Liu T, et al
    Persist or resist: Immune checkpoint inhibitors in EGFR-mutated NSCLC.
    Cancer Sci. 2025;116:581-591.
    >> Share

  51. CHEN Y, Pan G, Yang Y, Wu H, et al
    Tumor exosomal RNPEP promotes lung metastasis of liver cancer via inducing cancer-associated fibroblast activation.
    Cancer Sci. 2025;116:792-807.
    >> Share

    February 2025
  52. PAN Z, Qian Y, Wang Y, Zhang T, et al
    STAT3 Inhibition Prevents Adaptive Resistance and Augments NK Cell Cytotoxicity to KRAS(G12C) Inhibitors in Nonsmall Cell Lung Cancer.
    Cancer Sci. 2025 Feb 12. doi: 10.1111/cas.70017.
    >> Share

  53. OI H, Taki T, Kuroe T, Sakamoto N, et al
    NETosis in pulmonary pleomorphic carcinoma.
    Cancer Sci. 2025;116:524-532.
    >> Share

    January 2025
  54. WU Y, Cui Y, Zheng X, Yao X, et al
    Integrated machine learning to predict the prognosis of lung adenocarcinoma patients based on SARS-COV-2 and lung adenocarcinoma crosstalk genes.
    Cancer Sci. 2025;116:95-111.
    >> Share

    December 2024
  55. ZHAO Z, Bhardwaj M, Fan Z, Li X, et al
    Smoking-independent DNA methylation markers for lung cancer risk: External validation in a large population-based cohort study.
    Cancer Sci. 2024 Dec 3. doi: 10.1111/cas.16414.
    >> Share

  56. IWASAKI T, Shirota H, Sasaki K, Ouchi K, et al
    Specific cancer types and prognosis in patients with variations in the KEAP1-NRF2 system: A retrospective cohort study.
    Cancer Sci. 2024;115:4034-4044.
    >> Share

    November 2024
  57. KA M, Matsumoto Y, Ando T, Hinata M, et al
    Integrin-alpha5 expression and its role in non-small cell lung cancer progression.
    Cancer Sci. 2024 Nov 24. doi: 10.1111/cas.16416.
    >> Share

  58. SAKAI K, Ohara S, Tanaka J, Suda K, et al
    Improved platelet separation performance from whole blood using an acoustic fluidics system.
    Cancer Sci. 2024;115:3795-3803.
    >> Share

  59. TAKI T, Koike Y, Adachi M, Sakashita S, et al
    A novel histopathological feature of spatial tumor-stroma distribution predicts lung squamous cell carcinoma prognosis.
    Cancer Sci. 2024;115:3804-3816.
    >> Share

    October 2024
  60. XU F, Wang C, Li H, Yu B, et al
    Evaluation of cfDNA fragmentation characteristics in plasma for the diagnosis of lung cancer: A prospective cohort study.
    Cancer Sci. 2024 Oct 28. doi: 10.1111/cas.16360.
    >> Share

    September 2024
  61. FURUTA M, Horinouchi H, Yokota I, Yamaguchi T, et al
    Durvalumab after chemoradiotherapy for locoregional recurrence of completely resected non-small-cell lung cancer (NEJ056).
    Cancer Sci. 2024 Sep 15. doi: 10.1111/cas.16340.
    >> Share

  62. NISHITSUJI K, Mito R, Ikezaki M, Yano H, et al
    Impacts of cytoplasmic p53 aggregates on the prognosis and the transcriptome in lung squamous cell carcinoma.
    Cancer Sci. 2024;115:2947-2960.
    >> Share

    August 2024
  63. WU ZY, Yang DW, He YQ, Wang TM, et al
    Plasma ofCS-modified CD44 predicts the survival of patients with lung cancer.
    Cancer Sci. 2024 Aug 27. doi: 10.1111/cas.16319.
    >> Share

  64. ONDA N, Nakamichi S, Hirao M, Matsuda K, et al
    Afatinib plus PEM and CBDCA overcome osimertinib resistance in EGFR-mutated NSCLC with high thrombospondin-1 expression.
    Cancer Sci. 2024;115:2718-2728.
    >> Share

  65. FUJIKAWA Y, Kawabata S, Tsujino K, Yamada H, et al
    Boron neutron capture therapy delays the decline in neurological function in a mouse model of metastatic spinal tumors.
    Cancer Sci. 2024;115:2774-2785.
    >> Share

  66. SHI Y, Zhang J, Li J, He J, et al
    USP15, activated by TFAP4 transcriptionally, stabilizes SHC1 via deubiquitination and deteriorates renal cell carcinoma.
    Cancer Sci. 2024;115:2617-2629.
    >> Share

  67. LI C, Hu M, Cai S, Yang G, et al
    Dysfunction of CD8(+) T cells around tumor cells leads to occult lymph node metastasis in NSCLC patients.
    Cancer Sci. 2024;115:2528-2539.
    >> Share

    July 2024
  68. AHAMED MT, Forshed J, Levitsky A, Lehtio J, et al
    Multiplex plasma protein assays as a diagnostic tool for lung cancer.
    Cancer Sci. 2024 Jul 30. doi: 10.1111/cas.16300.
    >> Share

  69. MATSUI Y, Yamada T, Katayama Y, Hirai S, et al
    Initial AXL and MCL-1 inhibition contributes to abolishing lazertinib tolerance in EGFR-mutant lung cancer cells.
    Cancer Sci. 2024 Jul 22. doi: 10.1111/cas.16292.
    >> Share

  70. WANG Y, Ma L, Chen Y, Yun W, et al
    Prognostic effect of TCF1+ CD8+ T cell and TOX+ CD8+ T cell infiltration in lung adenocarcinoma.
    Cancer Sci. 2024;115:2184-2195.
    >> Share

    June 2024
  71. SHAO Y, Zhang J, Feng Z, Wu W, et al
    Outcomes in non-small cell lung cancer with uncommon epidermal growth factor receptor L858 substitutions under first-line epidermal growth factor receptor tyrosine kinase inhibitors: A large real-world cohort study.
    Cancer Sci. 2024 Jun 26. doi: 10.1111/cas.16250.
    >> Share

  72. ZHANG C, Yang L, Zhao W, Zhu H, et al
    A heterogeneous tumor immune microenvironment of uncommon epidermal growth factor receptor mutant non-small cell lung cancer.
    Cancer Sci. 2024 Jun 18. doi: 10.1111/cas.16253.
    >> Share

  73. WANG J, Wang S, Yang H, Wang R, et al
    Methyltransferase like-14 suppresses growth and metastasis of non-small-cell lung cancer by decreasing LINC02747.
    Cancer Sci. 2024 Jun 18. doi: 10.1111/cas.16254.
    >> Share

  74. GUO Y, Kasai Y, Tanaka Y, Ohashi-Kumagai Y, et al
    IGSF3 is a homophilic cell adhesion molecule that drives lung metastasis of melanoma by promoting adhesion to vascular endothelium.
    Cancer Sci. 2024;115:1936-1947.
    >> Share

  75. FUKUDA H, Arai K, Mizuno H, Nishito Y, et al
    Molecular subtypes of lung adenocarcinoma present distinct immune tumor microenvironments.
    Cancer Sci. 2024;115:1763-1777.
    >> Share

  76. RAUT JR, Bhardwaj M, Schottker B, Holleczek B, et al
    Cancer-specific risk prediction with a serum microRNA signature.
    Cancer Sci. 2024;115:2049-2058.
    >> Share

    May 2024
  77. SHIBA-ISHII A, Takemura N, Kawai H, Matsubara D, et al
    Histologic transformation of non-small-cell lung cancer in response to tyrosine kinase inhibitors: Current knowledge of genetic changes and molecular mechanisms.
    Cancer Sci. 2024 May 27. doi: 10.1111/cas.16192.
    >> Share

  78. DUCH P, Diaz-Valdivia N, Gabasa M, Ikemori R, et al
    Aberrant TIMP-1 production in tumor-associated fibroblasts drives the selective benefits of nintedanib in lung adenocarcinoma.
    Cancer Sci. 2024;115:1505-1519.
    >> Share

    April 2024
  79. ZHANG C, Sun N, Fei Q, Peng L, et al
    MEN1 deficiency stabilizes PD-L1 and promotes tumor immune evasion of lung cancer.
    Cancer Sci. 2024 Apr 30. doi: 10.1111/cas.16196.
    >> Share

  80. OTANI Y, Katayama H, Zhu Y, Huang R, et al
    Adrenergic microenvironment driven by cancer-associated Schwann cells contributes to chemoresistance in patients with lung cancer.
    Cancer Sci. 2024 Apr 27. doi: 10.1111/cas.16164.
    >> Share

  81. ALANAZI M, Weng T, McLeod L, Gearing LJ, et al
    Cytosolic DNA sensor AIM2 promotes KRAS-driven lung cancer independent of inflammasomes.
    Cancer Sci. 2024 Apr 9. doi: 10.1111/cas.16171.
    >> Share

  82. MORISE M, Kato T, Matsumoto S, Inoue T, et al
    Long-term experience with tepotinib in Japanese patients with MET exon 14 skipping NSCLC from the Phase II VISION study.
    Cancer Sci. 2024;115:1296-1305.
    >> Share

  83. MIZOTE Y, Inoue T, Akazawa T, Kunimasa K, et al
    Potent CTLs can be induced against tumor cells in an environment of lower levels of systemic MFG-E8.
    Cancer Sci. 2024;115:1114-1128.
    >> Share

    March 2024

  84. Correction to: Phytochemical library screening reveals betulinic acid as a novel Skp2-SCF E3 ligase inhibitor in non-small cell lung cancer.
    Cancer Sci. 2024 Mar 20. doi: 10.1111/cas.16163.
    >> Share

  85. ISHIDA M, Iwasaku M, Doi T, Ishikawa T, et al
    Nationwide data from comprehensive genomic profiling assays for detecting driver oncogenes in non-small cell lung cancer.
    Cancer Sci. 2024 Mar 7. doi: 10.1111/cas.16130.
    >> Share

  86. WANG S, Wang J, Gong W, Zhang F, et al
    ILT4 facilitates angiogenesis in non-small cell lung cancer.
    Cancer Sci. 2024 Mar 3. doi: 10.1111/cas.16126.
    >> Share

    February 2024
  87. KAJIWARA N, Kakihana M, Maeda J, Kaneko M, et al
    Salivary metabolomic biomarkers for non-invasive lung cancer detection.
    Cancer Sci. 2024 Feb 28. doi: 10.1111/cas.16112.
    >> Share

  88. KAWAI S, Lin Y, Tsuge H, Ito H, et al
    Body mass index and lung cancer risk: Pooled analysis of 10 prospective cohort studies in Japan.
    Cancer Sci. 2024 Feb 4. doi: 10.1111/cas.16093.
    >> Share

  89. YONEDA H, Mitsuhashi A, Yoshida A, Ogino H, et al
    Antipodoplanin antibody enhances the antitumor effects of CTLA-4 blockade against malignant mesothelioma by natural killer cells.
    Cancer Sci. 2024;115:357-368.
    >> Share

  90. HASEGAWA S, Shintani Y, Takuwa T, Aoe K, et al
    Nationwide prospective registry database of patients with newly diagnosed untreated pleural mesothelioma in Japan.
    Cancer Sci. 2024;115:507-528.
    >> Share

    January 2024
  91. TSUJI K, Mizugaki H, Yokoo K, Kobayashi M, et al
    Durvalumab after chemoradiotherapy in non-small cell lung cancer with EGFR mutation: A real-world study (HOT2101).
    Cancer Sci. 2024 Jan 29. doi: 10.1111/cas.16094.
    >> Share

  92. ZHANG J, Li Y, Yang Y, Huang J, et al
    A novel iTreg-related signature for prognostic prediction in lung adenocarcinoma.
    Cancer Sci. 2024;115:109-124.
    >> Share

    December 2023
  93. SHIMOMURA Y, Sawa K, Imai T, Ihara Y, et al
    Treatment sequencing after failure to alectinib in patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer.
    Cancer Sci. 2023 Dec 27. doi: 10.1111/cas.16056.
    >> Share

  94. HUANG R, Wu D, Zhang K, Hu G, et al
    ARID1A loss induces P4HB to activate fibroblasts to support lung cancer cell growth, invasion, and chemoresistance.
    Cancer Sci. 2023 Dec 15. doi: 10.1111/cas.16052.
    >> Share

  95. MITSUDOMI T, Ito H, Okada M, Sugawara S, et al
    Neoadjuvant nivolumab plus chemotherapy in resectable non-small-cell lung cancer in Japanese patients from CheckMate 816.
    Cancer Sci. 2023 Dec 14. doi: 10.1111/cas.16030.
    >> Share


  96. Correction to Brigatinib in Japanese patients with ALK-positive non-small-cell lung cancer: Final results of the phase 2 J-ALTA trial.
    Cancer Sci. 2023 Dec 10. doi: 10.1111/cas.16000.
    >> Share

  97. SUMITOMO R, Menju T, Shimazu Y, Toyazaki T, et al
    M2-like tumor-associated macrophages promote epithelial-mesenchymal transition through the transforming growth factor beta/Smad/zinc finger e-box binding homeobox pathway with increased metastatic potential and tumor cell proliferation in lung squamou
    Cancer Sci. 2023;114:4521-4534.
    >> Share

  98. WANG Q, Song X, Zhao F, Chen Q, et al
    Noninvasive diagnosis of pulmonary nodules using a circulating tsRNA-based nomogram.
    Cancer Sci. 2023;114:4607-4621.
    >> Share

    November 2023
  99. FUJIMOTO K, Matsumoto Y, Imabayashi T, Uchimura K, et al
    Suitability of respiratory endoscopy for sampling malignant thoracic tumors for comprehensive genomic profiling.
    Cancer Sci. 2023;114:4401-4412.
    >> Share

  100. KANG N, Fan B, Sun Y, Xue P, et al
    Novel specific anti-ESM1 antibodies overcome tumor bevacizumab resistance by suppressing angiogenesis and metastasis.
    Cancer Sci. 2023;114:4413-4425.
    >> Share

    October 2023
  101. NAKANISHI T, Yoneshima Y, Okamura K, Yanagihara T, et al
    MicroRNA-326 negatively regulates CD155 expression in lung adenocarcinoma.
    Cancer Sci. 2023;114:4101-4113.
    >> Share

  102. KUDO H, Morishima T, Fujii M, Nagayasu M, et al
    Prognostic impact of the presence or absence of prior cancer in patients with cancer using cure models: A population-based study.
    Cancer Sci. 2023;114:4041-4051.
    >> Share

    September 2023
  103. HUAI Q, Luo C, Song P, Bie F, et al
    Peripheral blood inflammatory biomarkers dynamics reflect treatment response and predict prognosis in non-small cell lung cancer patients with neoadjuvant immunotherapy.
    Cancer Sci. 2023 Sep 20. doi: 10.1111/cas.15964.
    >> Share

  104. ANDO C, Ichihara E, Nishi T, Morita A, et al
    Efficacy of gilteritinib in comparison with alectinib for the treatment of ALK-rearranged non-small cell lung cancer.
    Cancer Sci. 2023 Sep 15. doi: 10.1111/cas.15958.
    >> Share

  105. HINOKUMA H, Kanamori Y, Ikeda K, Hao L, et al
    Distinct functions between ferrous and ferric iron in lung cancer cell growth.
    Cancer Sci. 2023 Sep 8. doi: 10.1111/cas.15949.
    >> Share

  106. CHEN Y, Jin L, Ma Y, Liu Y, et al
    BACH1 promotes lung adenocarcinoma cell metastasis through transcriptional activation of ITGA2.
    Cancer Sci. 2023;114:3568-3582.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016